Eating More Fiber Reshapes Bile Acids in Ways That Could Supercharge Cancer Immunotherapy

A carefully controlled feeding study at MD Anderson Cancer Center has uncovered a molecular thread connecting what melanoma patients eat to how well their immune checkpoint drugs work. The culprit, or rather the beneficiary, turns out to be bile acids: gut bacteria convert dietary fiber into signals that appear to dial up the immune system's ability to attack tumors.

How a High-Fiber Diet Reduces Secondary Bile Acids in Melanoma Patients

The new analysis, published in the Journal of Clinical Oncology by Yan Jiang, Nazli Dizman, Jennifer Wargo, and colleagues, is a secondary objective of the DIET trial (NCT04645680). Forty-five melanoma patients starting immune checkpoint blockade (ICB) were randomized 2:1 to either a high-fiber diet of 30 to 50 grams per day or a healthy control diet of 20 grams per day, sustained for up to ten weeks. Serum samples from 43 of those patients underwent both untargeted metabolomics and targeted bile acid profiling using LC-MS/MS, a technique that can identify and quantify individual bile acid species with precision.

The high-fiber arm showed statistically significant reductions in secondary bile acids and their glycine- and taurine-conjugated derivatives compared to the control arm (p<0.05). Specifically, unconjugated secondary bile acids like deoxycholic acid and lithocholic acid fell, as did the ratio of secondary to primary bile acids. In plain terms: when patients ate more fiber, their gut bacteria converted fewer primary bile acids (such as cholic acid and chenodeoxycholic acid) into the secondary forms that may suppress immune activity.

Why Bile Acids Matter for Immune Checkpoint Blockade Response

Bile acids are not just digestive detergents. They are signaling molecules that interact with receptors throughout the gut and immune system, and research has shown that the gut microbiome strongly influences immunotherapy efficacy in melanoma. Secondary bile acids in particular have been associated with immunosuppressive effects, so reducing them is not a trivial housekeeping change. It is a potential mechanism by which diet reshapes the tumor immune environment.

This matters because ICB drugs, primarily PD-1 and CTLA-4 inhibitors, depend on an active immune response to work. A growing body of evidence, including a landmark Science study showing that a high-fiber diet improved melanoma anti-PD-1 immunotherapy responses, suggests the gut microbiome is a key co-regulator of that response. The MD Anderson team's finding that dietary fiber modulates the specific biochemical output of gut bacteria adds a plausible mechanistic layer to that association. More recently, a 2026 study reinforced that higher fiber intake correlates with clinical benefit from ICB in melanoma and sarcoma patients regardless of baseline microbiome composition, suggesting fiber's effects may be robust across different gut ecosystems.

Mouse Transplant Experiments Replicate the Bile Acid Shift

The team went a step further than blood samples. They conducted fecal microbiota transplants (FMTs), taking stool from melanoma patients before and after the high-fiber dietary period and transplanting it into mouse avatar models of melanoma. Mice receiving post-high-fiber FMTs showed improved ICB efficacy compared to those receiving pre-diet stool. Critically, those same mice also exhibited decreased secondary-to-primary bile acid ratios in circulation, mirroring the human data.

That replication in a controlled animal model is important. It suggests the bile acid shift is not merely a correlate of fiber intake but is carried by the microbiome itself: transplant the microbiome, transplant the bile acid signature, and apparently transplant some of the anti-tumor benefit. The mouse cohort was small, five animals in the FMT arm, so these results are hypothesis-generating rather than definitive, but they point the mechanistic arrow in a clear direction.

Small Cohort Size and the Need for Larger Validation

The targeted bile acid profiling focused on a subset of only 14 patients (six high-fiber, eight control) for the paired equilibration-versus-weeks-1-to-4 analysis, and the FMT experiments used just five mice. The overall trial enrolled 45 patients, which is modest for drawing firm clinical conclusions. The authors acknowledge that further mechanistic studies in preclinical models and validation in larger patient cohorts are both warranted.

It is also worth noting that this is a secondary objective of the DIET trial, not its primary endpoint. The primary feasibility results, published earlier, showed the high-fiber diet was safe and numerically associated with a higher ICB response rate, but that analysis was not powered to confirm a statistically significant survival benefit. The current metabolomics data add biological plausibility without yet proving clinical causality. Reviewers of personalized nutrition strategies in cancer immunotherapy have noted that the field still lacks the large, adequately powered trials needed to translate dietary signals into standard-of-care recommendations.

What Comes Next: Larger Trials and Precision Dietary Targeting

The MD Anderson team's roadmap calls for expanded mechanistic work in preclinical models and, ultimately, larger randomized trials that can link specific bile acid changes to clinical outcomes like progression-free survival and overall response rate. If the bile acid mechanism holds up, it opens a genuinely tractable intervention: unlike genetic mutations or tumor microenvironment features that clinicians cannot easily change, dietary fiber intake is modifiable.

The longer horizon involves matching dietary interventions to individual microbiome profiles. Researchers are already exploring how AI-driven precision nutrition could personalize cancer treatment based on a patient's unique gut ecosystem. For melanoma patients starting checkpoint inhibitors, the practical implication may be simple: eating more vegetables, legumes, and whole grains could do more than keep digestion comfortable; it may tip the biochemical balance in favor of the drugs already prescribed.